Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a medical research study to test a medication in patients 10 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of sodium phenylbutyrate in patients with MCADD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jerry Vockley, MD, PhD
• Collaborator: Acer Therapeutics Inc.
• Treatments: 4-phenylbutyric acid

Criteria

Inclusion Criteria:

• A diagnosis of MCADD and molecular confirmation of at least one copy of the common c.985A>G mutation.

• ≥16 years of age for cohort 1 and ≥10-15 years of age for cohort 2.

• Able to perform and comply with study activities including overnight admission to the PCTRC, placement of an IV catheter, and all blood draws.

• Negative pregnancy test for all female subjects of childbearing age.

• Signed informed consent by the subject or parent/guardian of minors.

• All females of childbearing age and all sexually active males must agree to use an acceptable method of contraception throughout the study. Appropriate contraceptive methods include hormonal contraceptives (oral, injected, implanted, or transdermal), tubal ligation, intrauterine device, hysterectomy, vasectomy, or double barrier methods. Abstinence is an acceptable form of birth control, though appropriate contraception must be used if the subject becomes sexually active.

Exclusion Criteria:

• Use of any investigational drug within 30 days of Day 1.

• Active infection (viral or bacterial) or any other intercurrent condition as reported by the subject or noted on physical exam at screening.

• Any clinical or laboratory abnormality of Grade 3 or greater severity according to the CTCAE v5.0, or Grade 3 elevations in liver enzymes, defined as levels 5-20 times ULN in alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), or gamma glutamyl transpeptidase (GGT) in a clinically stable subject.

• Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study.

• Use of any medication known to significantly affect renal clearance (e.g., probenecid) or to increase protein catabolism (e.g., corticosteroids), or other medication known to increase ammonia levels (e.g., valproic acid or haloperidol), within the 48 hours prior to Day 1 and throughout the study.

• Subjects with renal insufficiency will be excluded from the study. Cutoff eGFR <60 mL/min/1.73m2 (GFR categories G3a-G5) will be used as measure of renal insufficiency.

• Use of sodium benzoate within one week of Day 1.

• Known hypersensitivity to PAA or PBA.

• Breastfeeding or lactating females.

• Subjects at risk of hypokalemia due to pre-existing diagnosis or on medications that can cause hypokalemia.

• Subjects with type 1 or type 2 diabetes, or who take medications as part of their routine care that can cause hypoglycemia